Related by context. All words. (Click for frequent words.) 77 Initiates Phase II 76 Initiates Phase III 74 Meets Primary Endpoint 74 Pivotal Phase III 73 Completes Patient Enrollment 73 Confirmatory Phase 73 Successfully Completes Phase 73 NDA Submission 73 Receives Orphan Drug Designation 73 Initiates Enrollment 72 Phase III Pivotal 72 Phase III Clinical Trial 72 Initiate Phase 72 Initiates Phase 2b 71 Initiate Phase III 70 Initiates Clinical 70 Pivotal Phase 70 Phase III Trial 70 Initiates Clinical Trial 70 Phase 2b Clinical Trial 70 Prolongs Survival 70 Phase Ib IIa 70 Pivotal Trial 70 Completes Enrollment 69 Patient Enrollment 69 Hsp# Inhibitor 69 Phase IIb Trial 69 Novel Oral 69 Oral Fingolimod 69 Submits NDA 69 Files IND 69 Phase 2a Trial 69 Drug Fails 69 JAK Inhibitor 69 Pafuramidine 69 Initiate Clinical Trial 69 Presents Preclinical Data 69 Teva Provides Update 69 Phase #b/#a clinical 69 IND Filing 69 Diamyd Medical Diamyd 69 Drug Candidate 68 Granted Orphan Drug 68 First Patient Enrolled 68 Multiple Ascending Dose 68 Oral Insulin Capsule 68 Vascular Disrupting Agent 68 Pivotal Trials 68 Achieves Primary Endpoint 68 Dose Ranging 68 Receives Approvable Letter 68 Combination REOLYSIN R 68 Demonstrates Positive 68 Arthritis Drug 68 Prostate Cancer Vaccine 68 Phase 2b Study 68 First Patient Dosed 68 Gout Drug 68 Rheumatoid Arthritis Drug 68 Clinical Trial Results 68 JAK2 Inhibitor 68 Phase 1b Clinical Trial 68 Phase 2a Clinical Trial 68 Pulmonary Arterial Hypertension 68 Randomised 68 Schizophrenia Drug 68 Metastatic Melanoma 67 Heart Transplant Recipients 67 Investigational Compound 67 Glufosfamide 67 Commences Phase 67 Phase Ib II 67 FDA Accepts 67 Archexin 67 Completes Dosing 67 Phase IIb Clinical Trial 67 First Patient Treated 67 Testosterone Gel 67 Pooled Analysis 67 FDA Approvals 67 CRMD# 67 Pivotal Study 67 Adjuvant Treatment 67 Files Investigational 67 Severe Sepsis 67 HDAC Inhibitor 67 Advanced Melanoma 67 Phase 2b Trial 67 Present Preclinical Data 67 Lung Cancer Drug 67 Investigational Treatment 67 Investigational Drug 67 FOLOTYN ® 67 Multicenter Randomized 67 Randomized Phase II 67 SUTENT ® 67 Demonstrates Significant 67 Dose Ranging Study 67 Patient Enrolment 66 Oral Calcitonin 66 Epilepsy Drug 66 LibiGel ® 66 Demonstrates Efficacy 66 Schizophrenia Treatment 66 Clinical Trial Evaluating 66 Phase III Trials 66 Refractory Angina 66 Begins Dosing 66 Pivotal Phase II 66 Improves Survival 66 Gets FDA Clearance 66 Efficacy Trial 66 Fondaparinux 66 CCX# B 66 Initiated Phase 66 Pegloticase 66 Fast Track Status 66 Mylan Receives Approval 66 Diabetic Neuropathy 66 Phase III Clinical Trials 66 Orphan Status 66 Civacir 66 Initiates Phase 66 Antitumor Activity 66 Phase III HEAT 66 Randomized Double Blind 66 ThermoDox R 66 Submits Biologics License Application 66 Recurrent Glioblastoma 66 Receives CE Marking 66 induced macular edema 66 Resubmission 66 Receives Fast Track 66 lexidronam injection 66 IIa Clinical Trial 66 Rotavirus Vaccine 66 Hepatocellular Carcinoma 66 Novel Antibiotic 66 Reports Preclinical Data 66 Microplasmin 66 Receives Complete Response 66 Preclinical Data 66 Expanded Indication 66 Anti Inflammatory Drug 66 initiated Phase Ib 66 Inhaled Insulin 66 Announces Tentative Approval 66 Trial Evaluating 66 Dose Escalation 66 Tezampanel 66 DOR BioPharma Announces 66 Diabetic Nephropathy 66 BioSante Pharmaceuticals Announces 66 Personalized Immunotherapy 65 acetonide FA 65 Single Dose 65 reslizumab 65 PDUFA Date 65 Bazedoxifene 65 Receive Milestone Payment 65 Pirfenidone 65 Dalbavancin 65 Presents Preclinical 65 Dupuytren Contracture 65 Intravenous Formulation 65 Generic Version 65 Cetrorelix 65 Ridaforolimus 65 Receives Orphan Drug 65 Deforolimus 65 Phase IIb III 65 ENLIGHT 65 Ceflatonin R 65 Elagolix 65 Oral Insulin 65 Patients Receiving 65 Presents Positive 65 Pivotal Clinical Trial 65 Transdermal Patch 65 Second Pivotal Phase 65 MKC# MKC# PP 65 Milestone Payment From 65 Psoriasis Drug 65 HCV Protease Inhibitor 65 Randomized Double blind 65 Vaccine Candidate 65 Androxal TM 65 IND Application 65 Sunesis Pharma 65 Sapacitabine 65 Phase III multicenter 65 Receives Milestone Payment 65 Earns Milestone Payment 65 catheter occlusion 65 ISTODAX ® 65 Demonstrates Sustained 65 Oral Mucositis 65 Blood Pressure Drug 65 fosbretabulin 65 Milestone Payment 65 Melphalan 65 PresbyLens ® 65 ZOLINZA 65 Topline Results 65 Randomized Phase 65 Ranolazine 65 Systemic Delivery 64 Diabetic Foot Ulcer 64 XIAFLEX ® 64 Panzem R NCD 64 Patients Treated With 64 Shows Efficacy 64 Cloretazine ® 64 Aflibercept 64 Submits IND 64 LEVADEX TM 64 POSIDUR TM 64 docetaxel Taxotere ® 64 ARRY # 64 Luveniq 64 Receives Positive Opinion 64 PROVENGE ® 64 PHASE III 64 Phase IIIb 64 Immunomedics Announces 64 successfully commercialize Iluvien 64 LEP ETU 64 Anticancer Compound 64 PANVAC VF 64 Clinical Trial Data 64 MOVIPREP R 64 Cellegesic 64 Study Evaluating 64 II Clinical Trial 64 Anturol TM 64 Phase IIB 64 interferon gamma 1b 64 Myoblast 64 vinorelbine tartrate 64 Prospective Randomized 64 Sagent Pharmaceuticals Announces 64 Aeolus Pharmaceuticals Announces 64 Avian Flu Vaccine 64 Novel Compound 64 vapreotide acetate 64 Spectrum Pharmaceuticals Announces 64 TLK# 64 ONCONASE R 64 Vaccine Adjuvant 64 DIRECT Trial 64 Lupus Drug 64 Phase IIA 64 Dose Finding 64 Romidepsin 64 Commence Phase 64 RNAi Therapeutics 64 acyclovir Lauriad R 64 Cutaneous T 64 GW# [003] 64 ARIXTRA R 64 Zenvia Phase III 64 Acute Heart Failure 64 retinal vein occlusion induced 64 evaluating satraplatin 64 Golimumab 64 Onyx Pharmaceuticals Announces 64 Vicriviroc 64 Gastric Cancer 64 Deferiprone 64 Anti Tumor 64 BRIM2 64 Lupus Nephritis 64 Non Inferiority 64 Tesetaxel 64 Initiates Clinical Trials 64 Survival Benefit 64 Silodosin 64 Plaque Psoriasis 64 Submits Response 64 Commences Phase III 64 Gemzar ® 64 Taro Receives 64 FOLFOX6 chemotherapy regimen 64 Eluting Stent 64 L BLP# 64 Angiox ® 64 Cholesterol Drug 64 MAGE A3 ASCI 64 Begins Clinical Trial 64 Hormone Refractory Prostate Cancer 64 Confirms Efficacy 64 APEX PD 64 Postmenopausal Osteoporosis 64 forodesine 64 Acute Ischemic Stroke 63 Anemia Drug 63 Inhalation Solution 63 Panzem ® 63 Low Dose 63 Randomized Phase III 63 Initiates Dosing 63 Generic Versions 63 Sanvar R 63 Matrix Phase 2b 63 Ambrisentan 63 Anticancer Drug 63 FDA APPROVES 63 PDX pralatrexate 63 Phase IIIb clinical 63 Combination Treatment 63 TASKi3 63 Panzem R 63 Commercialize Novel 63 Desvenlafaxine Succinate 63 Well Tolerated 63 SPRYCEL ® 63 Investigational Oral 63 Recurrent Breast Cancer 63 methylnaltrexone bromide 63 Aurora Kinase 63 Refractory Hodgkin Lymphoma 63 including eniluracil ADH 63 Arthritis Drugs 63 Aryplase 63 TKB# 63 Pneumococcal Vaccine 63 Abstract Accepted 63 Long Term Efficacy 63 Crofelemer budesonide foam 63 Cethromycin 63 Protease Inhibitor 63 Safinamide 63 Phase Ib clinical 63 Tyrosine Kinase Inhibitor 63 Patient Outcomes 63 Novel Inhibitor 63 Randomized Clinical Trial 63 Hedgehog Pathway Inhibitor 63 Interferon Gamma 63 GATTEX TM 63 Nicotine Vaccine 63 randomized Phase IIb 63 phase IIb clinical 63 Febuxostat 63 Japanese Encephalitis Vaccine 63 MKC# MT 63 Phase #b/#a 63 multicentre randomized controlled 63 trastuzumab DM1 T DM1 63 Phase III ThermoDox 63 FDA Okays 63 Reveals Positive 63 Universal Flu Vaccine 63 dextromethorphan quinidine 63 LEVADEX ™ 63 Mycophenolate Mofetil 63 Boxed Warnings 63 PRN FDA Approves 63 ThermoDox ® clinical 63 SYCREST 63 BrachySil TM 63 Placebo Controlled Trial 63 VIVITROL ® 63 balsalazide tablet 63 Announce License Agreement 63 Diabetic Macular Edema 63 TM Drug Eluting 63 Complicated Skin 63 Subgroup Analysis 63 Adjunctive Therapy 63 Metastatic Colorectal Cancer 63 SPL# Gel vaginal microbicide 63 Velaglucerase Alfa 63 Nuvelo Announces 63 Supplemental Biologics License Application 63 Placebo controlled 63 Submits Application 63 Ecallantide 63 Salix Pharmaceuticals Announces 63 Acute Decompensated Heart Failure 63 Ticagrelor 63 Glatiramer Acetate 63 Peginterferon alfa 2b 63 INSPIRE Trial Phase III 63 phase IIa clinical 63 Sangamo BioSciences Announces 63 Lung Cancer Trial 63 docetaxel Taxotere R 63 Chronic Renal Failure 63 Improves Outcomes 63 CURRENT OASIS 7 63 Receives Tentative Approval 63 Multicenter Phase 63 Drug Shows Promise 63 MGd 63 Aztreonam Lysine 63 Medidur TM FA 63 Immunotherapeutic 63 Therapeutic Vaccine 63 Patients Enrolled 63 Delcath Phase III 63 PREOS R 63 Preclinical Study 63 Milestone Payments 63 Rheumatoid Arthritis Patients 63 Brentuximab Vedotin SGN 63 Develop Novel 63 pharmacogenomic translational research 63 MIVI III 62 UPLYSO 62 Expedited Review 62 Entereg R 62 Apaziquone 62 systemic immunosuppressive drugs 62 Migraine Drug 62 Bivalirudin 62 Soriatane 62 HuMax TAC 62 Rotavirus Vaccines 62 Toremifene 62 Simulect 62 Hepatitis B Vaccine 62 XYOTAX TM 62 Naive Patients 62 fidaxomicin Phase 62 rhIGF-I/rhIGFBP-3 62 Eniluracil 62 Novel Vaccine 62 Clinical Evaluation 62 Medicure Announces 62 Cholesterol Lowering Drug 62 Lenocta TM 62 albiglutide 62 PharmaVitae Profile 62 Efficacy Results 62 ALN HPN 62 MKC# 62 Osteoporosis Drug 62 Wafer polifeprosan 62 Cethrin R 62 Preclinical Models 62 Pemetrexed 62 Licenses Novel 62 candidates Azedra TM 62 oral ridaforolimus 62 Ophena 62 Antitumor 62 Acute Coronary Syndromes 62 Granulocyte Colony Stimulating Factor 62 oral prodrug 62 Recommends Approval 62 Phase Ib Clinical Trial 62 Bosutinib 62 Combo Therapy 62 Warfarin Coumadin 62 Fabry Disease 62 Carboplatin Paclitaxel 62 RNAi Therapeutic 62 Bayer Onyx 62 Generic Version Of 62 Preclinical Efficacy 62 Unstable Angina 62 REMINYL ® 62 Treated Patients 62 Relapsing Multiple Sclerosis 62 Renal Cancer 62 Generic Lovenox 62 Liprotamase 62 Announces Poster Presentations 62 R lenalidomide 62 Dyloject TM 62 ORENCIA R 62 PI3K/Akt pathway inhibitor 62 BARACLUDE R 62 Bayer HealthCare Onyx Pharmaceuticals 62 Fungal Infections 62 Nilotinib 62 Cervical Cancer Vaccine 62 Xcytrin R 62 Improved Survival 62 Prosecution Rests Case 62 Cloretazine 62 BR.# 62 Investigational Agent 62 Demonstrate Significant 62 Patients Suffering 62 Launches Generic Version 62 rasagiline tablets 62 Pralatrexate 62 oral salmon calcitonin 62 BENLYSTA ® 62 erlotinib Tarceva R 62 EVIZON TM 62 Antibody Drug Conjugate 62 J Am Coll 62 Obtains CE Mark 62 Randomized Clinical Trials 62 HDL Selective Delipidation 62 liver resection surgeries 62 Shows Promise Against 62 StemEx 62 Methylnaltrexone 62 Mg Usa 62 orally inhaled migraine 62 TRANSDUR ® 62 Neulasta R 62 randomized controlled multicenter 62 Unfractionated Heparin 62 dependent kinase inhibitor 62 Romiplostim 62 Optimer Pharma 62 Phase III confirmatory 62 LymphoStat B belimumab 62 Kinase Inhibitor 62 Factor VIIa 62 registrational Phase 62 delivers fluocinolone acetonide FA 62 Zenvia ™ 62 2 methoxyestradiol 62 alvespimycin 62 novel emulsion formulation 62 Regeneron Pharma 62 Vitrasert R 62 Surgical Mesh 62 evaluating tivozanib 62 Chronic Heart Failure 62 IMPACT DCM 62 RELOVAIR ™ 62 PrevOnco 62 DIFICID ™ 62 Gentamicin Surgical Implant 62 HCl Tablets 62 TRANSDUR ™ 62 phase IIb III 62 BRIM3 62 BLP# Liposome Vaccine 62 evaluating mipomersen 62 Phase 1a clinical 62 Cites Positive 62 ZEVALIN ® 62 BRILINTA 62 Embolic Protection Device 62 Benign Prostatic Hyperplasia 62 Syncria R 62 hypoxia activated prodrug 62 Lubiprostone 62 Max Neeman International 62 cathepsin K inhibitor 62 Demonstrates Potential 62 Catheter Associated 62 epoetin zeta 62 Ebola Vaccine 62 Proellex TM 62 LE SN# 62 Vaccine Adjuvants 62 Intervention Effectiveness 62 PF # [002] 62 Shingles Vaccine 62 lucinactant 62 Vidaza ® 62 Submits Supplemental 62 Serostim ® 62 Patient Accrual 62 Anticancer Activity 62 Moxifloxacin 62 Marketing Authorisation Application 62 SinuNase TM 62 Renal Cell Carcinoma 62 Montelukast 62 NEBIDO R 62 Vertebral Fracture 62 ORENCIA ® 62 VYVANSE TM lisdexamfetamine 62 Oral Spray 62 Medullary Thyroid Cancer 62 tiapamil 62 RhuDex 62 IL# PE#QQR 62 personalized cellular immunotherapy 62 Biomarker Study 62 Therapeutic Competitors Companies 62 Advanced Heart Failure 62 Treating Chronic 62 Enzyme Replacement Therapy 62 Blood Thinner 62 Plus Ribavirin 62 unique alkylating agent 61 Pazopanib 61 severe hypercholesterolemia 61 OMNARIS HFA 61 Companion Diagnostic 61 AVI BioPharma Announces 61 Treat Heart Failure 61 Fentanyl Patch 61 ENDEAVOR IV 61 Antithrombin 61 herpetic keratitis 61 Smallpox Vaccine 61 Drug Combo 61 CYT# potent vascular disrupting 61 Submits Investigational 61 ACTEMRA TM 61 DDP# 61 sapacitabine CYC# 61 TELINTRA R 61 Recombinant Human 61 Lispro 61 Anti Tumor Activity 61 Trandolapril 61 Enrolling Patients 61 Shows Promising 61 Darinaparsin 61 Trobalt 61 Levoleucovorin 61 Extended Release 61 Selective Electrochemical Tumor Ablation 61 SBIR Grant 61 Temodar ® 61 Vidaza R 61 blinded randomized placebo controlled 61 dose escalation clinical 61 placebo controlled Phase III 61 Bepreve TM 61 kidney urologic 61 Therapeutic Competitors companiesandmarkets.com adEgemonye 61 phase IIb trial 61 Prostate AdenoCarcinoma Treatment 61 Tumor Response 61 SANVAR 61 subcutaneous formulation 61 Treatment Resistant 61 IIa clinical 61 Pharmacokinetic Study 61 Relapsed Multiple Myeloma 61 Phase III Psoriasis 61 Resistant Hypertension 61 Drug Maker 61 Hypertensive Patients 61 Begin Clinical Trials 61 HGS ETR1 mapatumumab 61 CHMP Opinion 61 Tesamorelin 61 initiate Phase Ib 61 Announce Collaboration Agreement 61 Clinical Efficacy 61 Shows Statistically Significant 61 Kamada AAT 61 Overactive Bladder 61 ospemifene 61 Treatment Experienced 61 Elotuzumab 61 CB2 selective receptor agonist 61 Therapy Evaluation 61 TO AVOID PREGNANCY WHILE 61 Ultrafast Insulin 61 Oracea TM 61 Capsules CII 61 thorough QT 61 Enrolls First 61 Artery Disease 61 Catena ® 61 Drug Eluting Stent 61 multicenter Phase III 61 ADP receptor antagonist 61 Testosterone MDTS ® 61 Chronic Hepatitis C 61 Appears Safe 61 LUCASSIN 61 Treatment Regimen 61 Small Molecule 61 INTEGRILIN R 61 Diabetic Patients 61 Malignant Glioma 61 Curaxin CBLC# 61 novel VDA molecule 61 HER2 Positive Breast Cancer 61 HuMax EGFr 61 IV APAP 61 Stronger Warnings 61 AAG geldanamycin analog 61 Immunosuppressant 61 mertansine 61 Oxybutynin 61 LymphoStat B TM 61 hoFH 61 R#/MEM 61 Exelixis XL# 61 VISICOL R 61 KRYSTEXXA TM 61 Allovectin 7 61 Degarelix 61 Bipolar Mania 61 Clinical Outcome 61 Study Showed 61 FS Antihemophilic Factor Recombinant 61 Factor Xa Inhibitor 61 Neoadjuvant Chemotherapy 61 Genasense oblimersen sodium Injection 61 Patients Undergoing 61 telomerase therapeutic 61 CCR5 mAb 61 Antiviral Activity 61 miconazole Lauriad ® 61 Malaria Vaccine 61 AVANIR Pharmaceuticals Announces 61 PHX# 61 Treatment Naive Patients 61 Telithromycin 61 biliary tract cancer 61 Adjuvant Chemotherapy 61 Combination Therapy 61 Transdermal Delivery 61 Infected Patients 61 recurrent metastatic ovarian cancer 61 Acute Attacks 61 Phase IIa Clinical Trial 61 Prestara TM 61 pain palliation 61 Saforis 61 selective A2A adenosine receptor 61 Clinical Validation 61 Neoadjuvant 61 Intravitreal 61 Metabolic Disorder 61 Hedgehog Pathway 61 Clinically Significant 61 Trastuzumab DM1 61 Receives Favorable 61 granted Ortec 61 ® decitabine 61 Myocet 61 Replacement Therapy 61 orally administered inhibitor 61 Forodesine HCl 61 Orally Active 61 Inhalation Aerosol 61 FDA Clears 61 AEG# 61 Less Invasive 61 oral picoplatin 61 Kuvan R 61 Aloxi ® 61 GVAX ® 61 Cypher Sirolimus 61 rALLy clinical trial 61 CD# CEA 61 bardoxolone 61 Amoxicillin PULSYS Phase III 61 Issued Patent 61 Hydrochlorothiazide Tablets 61 Bicifadine 61 Interferon Alfa 61 Influenza Vaccine Production 61 Hospital Acquired Pneumonia 61 Monotherapy 61 By JENNIFER LEARN 61 NMT Medical Announces 61 Colorectal Cancer Patients 61 Aliskiren 61 Previously Treated 61 Argatroban 61 Elderly Patients 61 Vildagliptin 61 Zemplar Capsules 61 Xeloda ® 61 Bronchiectasis 61 Potent Antiviral Activity 61 Kuvan TM sapropterin 61 Zerenex ™ 61 novel oral anticoagulant 61 OMAPRO ™ 61 Desvenlafaxine 61 Carotid Artery Stenting 61 Announces FDA Clearance 61 LUMINATE 61 Seasonal Influenza Vaccine 61 Treatment Naïve 61 evaluating picoplatin 61 subcutaneous Herceptin 61 oral deforolimus 61 implantable centrifugal rotary 61 Peginterferon 61 Versus Placebo 61 Preotact R 61 Bipolar Depression 61 Kidney Transplant Patients 61 YONDELIS 61 Advaxis Phase 61 Receives SFDA Approval 61 Renal Function 61 Inhaled Corticosteroids 61 MYCAMINE 61 KRYSTEXXA TM pegloticase 61 Rigel R# 61 Improve Survival 61 Chronic Hepatitis B 61 BLA filing 61 Soft Tissue Sarcoma 61 octreotide acetate 61 Accelerated Approval 61 Is Well Tolerated 61 cinacalcet HCl 61 Antisoma AS# 61 JAK inhibitor 61 Randomized controlled 61 pralatrexate injection folate analogue 61 Vaccine Protects Against 61 Icatibant 61 Newly Diagnosed Multiple Myeloma 61 Ketotransdel 61 Motexafin Gadolinium 61 Advanced Renal Cell 61 STERIS Corporation Announces 61 NICE Recommends 61 5 HT3 antagonist 61 Hepatotoxicity 61 IMPACT IMmunotherapy 61 VIVUS Announces 61 Cardiotoxicity 61 Randomized Evaluation 61 Clinical Trial 61 Tamibarotene 60 Perforomist ™ Inhalation Solution 60 Heart Failure Patients 60 Onconase 60 Anticancer Agent 60 Restanza TM 60 MEK Inhibitor 60 Demonstrates Potent 60 acute peripheral arterial 60 refractory chronic lymphocytic 60 DP VPA 60 Flamel Technologies Announces 60 AVN# Phase 60 Positive Opinion 60 ZK EPO 60 HCl Injection 60 Progressive Multifocal Leukoencephalopathy 60 HCl capsules 60 alfa 2a 60 BioSante Pharmaceuticals Reports 60 Disease Modifying 60 Full Prescribing Information 60 Patent Infringement Litigation 60 Interferon Beta 60 Release Capsules 60 Orally administered 60 Active Ulcerative Colitis 60 investigational antiplatelet agent 60 Interspinous Spacer 60 REG1 Anticoagulation System 60 ZFP Therapeutics 60 Previously Disclosed 60 Augment TM 60 See CLINICAL PHARMACOLOGY 60 XL# anticancer compounds 60 cMET 60 myelodysplastic myeloproliferative diseases 60 PROSTASCINT R 60 Generic Protonix 60 Prochymal TM 60 Glycopyrrolate 60 Antidepressant Drug 60 pregabalin Lyrica 60 Surfaxin LS 60 Treat Anemia 60 Antiplatelet Therapy 60 Interferon beta 1a 60 RE MODEL 60 investigational humanized monoclonal antibody 60 Stem Cell Treatment 60 Disease Progression 60 chronic myocardial ischemia 60 diarrhea fatigue asthenia 60 Secondary Hyperparathyroidism 60 markets HP Acthar 60 Significantly Reduces 60 ELADUR ™ 60 CA9 SCAN 60 topically applied SEPA 60 TBC# 60 Bucindolol 60 Topical Treatment 60 C1 Inhibitor 60 Patent Covering 60 INCB# [001] 60 XL# XL# 60 Pegylated Liposomal Doxorubicin 60 Atypical Hemolytic Uremic Syndrome 60 OLpur TM H2H 60 AA Amyloidosis 60 signal detection CTSD 60 Telatinib 60 Zemiva TM 60 Chemophase 60 CCR9 antagonist 60 Pandemic Influenza Vaccine 60 #-# Full Text 60 Exherin 60 Iluvien TM 60 Double Blind Placebo 60 R#/MEM # 60 KRN# 60 Preliminary Injunction Against 60 Fixed Dose 60 Nipent R 60 Lysteda 60 nasal calcitonin product 60 SFDA Approval 60 assessing T DM1 60 topical gel formulation 60 Pandemic Influenza Vaccines 60 Drug Eluting Stent System 60 Myocardial Perfusion Imaging 60 Chemotherapeutic Agents 60 Somatuline R Autogel R 60 IMC #B 60 ongoing Phase 1b 60 Dapagliflozin 60 Antigen Specific 60 TAXUS Element Paclitaxel Eluting 60 PROTEGE 60 Anthrax Vaccine 60 keloid scarring 60 icatibant 60 Dasatinib 60 Orapred ODT 60 Pharmacokinetics PK 60 sorafenib tablets 60 phase Ib clinical 60 Neutrolin 60 Diabetic Foot Ulcers 60 Receives Marketing Authorization 60 Antiarrhythmic 60 Humanized Anti 60 FDA Approvable Letter 60 Hypercholesterolemia 60 GEM OS2 60 Systemic Sclerosis 60 Augment ™ 60 Anti Clotting Drug 60 pharmacokinetic PK study 60 Sevelamer 60 Inflammatory Arthritis 60 CTAP# Capsules 60 XIENCE V Stent System 60 Bicalutamide 60 sunitinib malate 60 Dual Opioid 60 TRIOLEX ™ 60 Regenerative Cells 60 telaprevir VX 60 Major Depressive Disorder MDD 60 samarium Sm 60 Reduces Mortality 60 Prostate Cancer Patients 60 Inhaled Nitric Oxide 60 AERx iDMS 60 Aviptadil 60 Tolvaptan 60 Key Milestones 60 Vascular Wrap TM 60 Allovectin 7 r 60 Medoxomil 60 GATTEX ™ 60 Palifosfamide 60 Node Positive 60 RECOTHROM R 60 reduce serum phosphate 60 5 Fluorouracil 60 Drug Approvals 60 Million Milestone Payment 60 Fludara ® 60 AzaSite Plus 60 Enlarged Prostate 60 PrevOnco ™ 60 Advanced Colorectal Cancer 60 Prestara 60 Prophylactic Treatment 60 REVEAL Registry 60 Approvable 60 Cardiac Resynchronization Therapy 60 candidate deforolimus 60 Controlled Study 60 Patients Treated 60 fondaparinux sodium 60 inhaled AAT 60 Alfimeprase 60 Current Controlled Trials 60 Phase 2a Study 60 Presents Positive Preclinical 60 TRANSDUR Bupivacaine 60 Clolar ® 60 Tigecycline 60 ChemGenex Pharmaceuticals Limited 60 multicenter Phase II 60 Decompensated Heart Failure 60 TM Everolimus Eluting 60 initiated Phase 1b